oral vancomycin
oral vancomycin is a pharmaceutical drug with 17 clinical trials. Currently 4 active trials ongoing. Historical success rate of 63.6%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
7
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
63.6%
7 of 11 finished
36.4%
4 ended early
4
trials recruiting
17
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
Maternal Probiotic Intervention to Improve Gut Health - Trial II - Bangladesh
Maternal Probiotic Intervention to Improve Gut Health - Trial II - Burkina Faso (MPIGH-II)
Maternal Probiotic Intervention to Improve Gut Health-Trial II-Pakistan
Beneficial Bacteria Treatment for Autism
Clinical Trials (17)
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
Maternal Probiotic Intervention to Improve Gut Health - Trial II - Bangladesh
Maternal Probiotic Intervention to Improve Gut Health - Trial II - Burkina Faso (MPIGH-II)
Maternal Probiotic Intervention to Improve Gut Health-Trial II-Pakistan
Beneficial Bacteria Treatment for Autism
Vancomycin in Primary Sclerosing Cholangitis in Italy
VE303 for Treatment of Hepatic Encephalopathy (HE)
Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients
Oral Vancomycin Vs Placebo in the Prevention of Recurrence of Clostridioides Difficile's Infection
Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics
Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)
A Systems Biology Approach for Identification of Host and Microbial Mechanisms and Druggable Targets for the Treatment of PSC-IBD
TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment
Oral Vancomycin for Preventing Clostridium Difficile Recurrence
First-in-human Study of VE303 in Healthy Adult Volunteers
Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
All 17 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 17